MINNEAPOLIS, March 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region and support the company's long-term regional growth strategy.
The new Customer Experience Centre is scheduled to open in summer 2026 and will feature a state-of-the-art Demonstration Laboratory hosting Bio-Techne's full instrument portfolio, including:
"Our new Customer Experience Centre will complement our existing Demonstration Laboratory in the UK, enabling us to provide more customers with hands-on experience of our unique instrument portfolio, and demonstrate how our solutions can accelerate their cutting-edge science and bring next generation therapies to market faster," said Dr. Peter Schuessler, Vice President, EMEA, Bio-Techne.
The facility's capacity will enable Bio-Techne to grow its customer-facing team in EMEA and support long-term regional growth, including in the large German market.
Düsseldorf was carefully chosen as the site for this new centre due to its thriving life sciences sector and strategic proximity to the Benelux region, providing seamless access to customers from multiple European markets.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
This email address is being protected from spambots. You need JavaScript enabled to view it.
612-656-4416
| Last Trade: | US$48.81 |
| Daily Change: | -3.50 -6.69 |
| Daily Volume: | 3,076,759 |
| Market Cap: | US$7.760B |
February 27, 2025 February 20, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
